Elective induction at 39 weeks of gestation and the implications of a large, multicenter, randomized controlled trial

Caroline Marrs, Mauricio La Rosa, Aaron Caughey, George Saade

Research output: Contribution to journalReview article

Abstract

On August 8, 2018, Grobman et al published the findings from the ARRIVE (A Randomized Trial of Induction Versus Expectant Management) trial, a large randomized controlled trial of elective induction of labor in nulliparous women at 39 weeks of gestation compared with expectant management. Conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, the trial found there was no difference between the two groups in the primary outcome, a composite of neonatal morbidity. Also, there was a reduction in rates of cesarean delivery and hypertensive disorders of pregnancy in the elective induction group. The topic of elective induction has been of interest to clinicians for decades, and research has yielded inconsistent results in the past. This trial offers the best evidence thus far to address this complex issue. Our objective is to briefly review the history and literature regarding elective induction of labor, discuss the recently published ARRIVE trial, and consider its implications on clinical practice and health policy.

Original languageEnglish (US)
Pages (from-to)445-450
Number of pages6
JournalObstetrics and gynecology
Volume133
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Induced Labor
Randomized Controlled Trials
National Institute of Child Health and Human Development (U.S.)
Pregnancy
Health Policy
History
Mothers
Medicine
Morbidity
Research

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Elective induction at 39 weeks of gestation and the implications of a large, multicenter, randomized controlled trial. / Marrs, Caroline; La Rosa, Mauricio; Caughey, Aaron; Saade, George.

In: Obstetrics and gynecology, Vol. 133, No. 3, 01.03.2019, p. 445-450.

Research output: Contribution to journalReview article

@article{d5306c68bf53419e9499f479082de7a0,
title = "Elective induction at 39 weeks of gestation and the implications of a large, multicenter, randomized controlled trial",
abstract = "On August 8, 2018, Grobman et al published the findings from the ARRIVE (A Randomized Trial of Induction Versus Expectant Management) trial, a large randomized controlled trial of elective induction of labor in nulliparous women at 39 weeks of gestation compared with expectant management. Conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, the trial found there was no difference between the two groups in the primary outcome, a composite of neonatal morbidity. Also, there was a reduction in rates of cesarean delivery and hypertensive disorders of pregnancy in the elective induction group. The topic of elective induction has been of interest to clinicians for decades, and research has yielded inconsistent results in the past. This trial offers the best evidence thus far to address this complex issue. Our objective is to briefly review the history and literature regarding elective induction of labor, discuss the recently published ARRIVE trial, and consider its implications on clinical practice and health policy.",
author = "Caroline Marrs and {La Rosa}, Mauricio and Aaron Caughey and George Saade",
year = "2019",
month = "3",
day = "1",
doi = "10.1097/AOG.0000000000003137",
language = "English (US)",
volume = "133",
pages = "445--450",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Elective induction at 39 weeks of gestation and the implications of a large, multicenter, randomized controlled trial

AU - Marrs, Caroline

AU - La Rosa, Mauricio

AU - Caughey, Aaron

AU - Saade, George

PY - 2019/3/1

Y1 - 2019/3/1

N2 - On August 8, 2018, Grobman et al published the findings from the ARRIVE (A Randomized Trial of Induction Versus Expectant Management) trial, a large randomized controlled trial of elective induction of labor in nulliparous women at 39 weeks of gestation compared with expectant management. Conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, the trial found there was no difference between the two groups in the primary outcome, a composite of neonatal morbidity. Also, there was a reduction in rates of cesarean delivery and hypertensive disorders of pregnancy in the elective induction group. The topic of elective induction has been of interest to clinicians for decades, and research has yielded inconsistent results in the past. This trial offers the best evidence thus far to address this complex issue. Our objective is to briefly review the history and literature regarding elective induction of labor, discuss the recently published ARRIVE trial, and consider its implications on clinical practice and health policy.

AB - On August 8, 2018, Grobman et al published the findings from the ARRIVE (A Randomized Trial of Induction Versus Expectant Management) trial, a large randomized controlled trial of elective induction of labor in nulliparous women at 39 weeks of gestation compared with expectant management. Conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, the trial found there was no difference between the two groups in the primary outcome, a composite of neonatal morbidity. Also, there was a reduction in rates of cesarean delivery and hypertensive disorders of pregnancy in the elective induction group. The topic of elective induction has been of interest to clinicians for decades, and research has yielded inconsistent results in the past. This trial offers the best evidence thus far to address this complex issue. Our objective is to briefly review the history and literature regarding elective induction of labor, discuss the recently published ARRIVE trial, and consider its implications on clinical practice and health policy.

UR - http://www.scopus.com/inward/record.url?scp=85062110849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062110849&partnerID=8YFLogxK

U2 - 10.1097/AOG.0000000000003137

DO - 10.1097/AOG.0000000000003137

M3 - Review article

VL - 133

SP - 445

EP - 450

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 3

ER -